Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 81

1.

Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment.

Pisaturo M, Starace M, Minichini C, De Pascalis S, Macera M, Occhiello L, Messina V, Sangiovanni V, Claar E, Precone D, Stornaiuolo G, Stanzione M, Gentile I, Brancaccio G, Martini S, Masiello A, Megna AS, Coppola C, Federico A, Sagnelli E, Persico M, Lanza AG, Marrone A, Gaeta GB, Coppola N.

Antivir Ther. 2019 Feb 13. doi: 10.3851/IMP3296. [Epub ahead of print]

PMID:
30758299
2.

Kerion mimicking an erosive pustular dermatosis of the scalp.

Magri F, Pranteda G, Federico A, Muscianese M, Pigliacelli F, D'arino A, Paolino G, Bottoni U, Pranteda G.

G Ital Dermatol Venereol. 2019 Feb;154(1):96-98. doi: 10.23736/S0392-0488.17.05673-5. No abstract available.

PMID:
30616337
3.

The management of pseudomyogenic hemangioendothelioma of the foot: A case report and review of the literature.

Pranteda G, Magri F, Muscianese M, Pigliacelli F, D'Arino A, Federico A, Pranteda G, Bartolazzi A.

Dermatol Ther. 2018 Nov;31(6):e12725. doi: 10.1111/dth.12725. Epub 2018 Sep 21. Review.

PMID:
30239066
4.

Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease.

Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A, Loguercio C, Federico A, Persico M.

Oxid Med Cell Longev. 2018 Jun 11;2018:9547613. doi: 10.1155/2018/9547613. eCollection 2018. Review.

5.

Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego AL, Brunetto MR, Raimondo G, Taliani G, Iannone A, Russo FP, Santantonio TA, Zuin M, Chessa L, Blanc P, Puoti M, Vinci M, Erne EM, Strazzabosco M, Massari M, Lampertico P, Rumi MG, Federico A, Orlandini A, Ciancio A, Borgia G, Andreone P, Caporaso N, Persico M, Ieluzzi D, Madonia S, Gori A, Gasbarrini A, Coppola C, Brancaccio G, Andriulli A, Quaranta MG, Montilla S, Razavi H, Melazzini M, Vella S, Craxì A; PITER Collaborating Group.

Liver Int. 2018 Dec;38(12):2190-2198. doi: 10.1111/liv.13901. Epub 2018 Aug 10.

6.

Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.

Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, Levantesi F, Airoldi A, Boccia S, Svegliati-Baroni G, Fagiuoli S, Romanelli RG, Cozzolongo R, Di Marco V, Sangiovanni V, Morisco F, Toniutto P, Tortora A, De Marco R, Angelico M, Cacciola I, Elia G, Federico A, Massironi S, Guarisco R, Galioto A, Ballardini G, Rendina M, Nardelli S, Piano S, Elia C, Prestianni L, Cappa FM, Cesarini L, Simone L, Pasquale C, Cavallin M, Andrealli A, Fidone F, Ruggeri M, Roncadori A, Baldassarre M, Tufoni M, Zaccherini G, Bernardi M; ANSWER Study Investigators.

Lancet. 2018 Jun 16;391(10138):2417-2429. doi: 10.1016/S0140-6736(18)30840-7. Epub 2018 Jun 1. Erratum in: Lancet. 2018 Aug 4;392(10145):386.

PMID:
29861076
7.

Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota.

Morgillo F, Dallio M, Della Corte CM, Gravina AG, Viscardi G, Loguercio C, Ciardiello F, Federico A.

Neoplasia. 2018 Jul;20(7):721-733. doi: 10.1016/j.neo.2018.05.002. Epub 2018 May 30. Review. No abstract available.

8.

Vascular Endothelial Dysfunction in Inflammatory Bowel Diseases: Pharmacological and Nonpharmacological Targets.

Gravina AG, Dallio M, Masarone M, Rosato V, Aglitti A, Persico M, Loguercio C, Federico A.

Oxid Med Cell Longev. 2018 Apr 12;2018:2568569. doi: 10.1155/2018/2568569. eCollection 2018. Review.

9.

Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.

Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A; ABACUS Study Group.

Infection. 2018 Oct;46(5):607-615. doi: 10.1007/s15010-018-1157-x. Epub 2018 May 28.

PMID:
29808463
10.

Correction to: "Non alcoholic fatty liver disease and eNOS dysfunction in humans".

Persico M, Masarone M, Damato A, Ambrosio M, Federico A, Rosato V, Bucci T, Carrizzo A, Vecchione C.

BMC Gastroenterol. 2017 Nov 8;17(1):116. doi: 10.1186/s12876-017-0671-0.

11.

Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer.

Belli V, Sforza V, Cardone C, Martinelli E, Barra G, Matrone N, Napolitano S, Morgillo F, Tuccillo C, Federico A, Dallio M, Loguercio C, Gravina AG, De Palma R, Ciardiello F, Troiani T.

Oncotarget. 2017 Aug 7;8(40):68305-68316. doi: 10.18632/oncotarget.20054. eCollection 2017 Sep 15.

12.

Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis.

Federico A, Dallio M, Caprio GG, Gravina AG, Picascia D, Masarone M, Persico M, Loguercio C.

Nutrients. 2017 Sep 28;9(10). pii: E1074. doi: 10.3390/nu9101074.

13.

Gut microbiota and the liver.

Federico A, Dallio M, Caprio GG, Ormando VM, Loguercio C.

Minerva Gastroenterol Dietol. 2017 Dec;63(4):385-398. doi: 10.23736/S1121-421X.17.02375-3. Review.

PMID:
28927250
14.

Gut microbiota, obesity and metabolic disorders.

Federico A, Dallio M, DI Sarno R, Giorgio V, Miele L.

Minerva Gastroenterol Dietol. 2017 Dec;63(4):337-344. doi: 10.23736/S1121-421X.17.02376-5. Review.

PMID:
28927249
15.

Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study.

Dallio M, Masarone M, Caprio GG, Di Sarno R, Tuccillo C, Sasso FC, Persico M, Loguercio C, Federico A.

J Gastrointestin Liver Dis. 2017 Sep;26(3):261-268. doi: 10.15403/jgld.2014.1121.263.dal.

16.

Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis.

Persico M, Rosato V, Aglitti A, Precone D, Corrado M, De Luna A, Morisco F, Camera S, Federico A, Dallio M, Claar E, Caporaso N, Masarone M.

Antivir Ther. 2018;23(2):129-138. doi: 10.3851/IMP3186.

PMID:
28799522
17.

Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma.

Persico M, Aglitti A, Caruso R, De Renzo A, Selleri C, Califano C, Abenavoli L, Federico A, Masarone M.

Hepatology. 2018 Jan;67(1):48-55. doi: 10.1002/hep.29364. Epub 2017 Nov 24.

PMID:
28714143
18.

A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells.

Federico A, Conti V, Russomanno G, Dallio M, Masarone M, Stiuso P, Tuccillo C, Caraglia M, Manzo V, Persico M, Filippelli A, Loguercio C.

In Vivo. 2017 Jul-Aug;31(4):609-618.

19.

Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.

Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team.

Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10. Erratum in: Lancet Gastroenterol Hepatol. 2017 Jun;2(6):e3.

PMID:
28497758
20.

Distinct metaplastic and inflammatory phenotypes in autoimmune and adenocarcinoma-associated chronic atrophic gastritis.

Jeong S, Choi E, Petersen CP, Roland JT, Federico A, Ippolito R, D'Armiento FP, Nardone G, Nagano O, Saya H, Romano M, Goldenring JR.

United European Gastroenterol J. 2017 Feb;5(1):37-44. doi: 10.1177/2050640616644142. Epub 2016 Jun 23.

Supplemental Content

Loading ...
Support Center